February was a month of trials beginning enrolment, novel technologies, and treatment protocols, with Gianmarco Falcone emphasising the need for a full protocol and multidisciplinary team for endovascular arteriovenous fistulas (endoAVF), and the first subjects being enrolled in in a US clinical trial for a novel bioabsorbable prevascular wrap.
At the most recent Paris Vascular Insights (PVI) meeting (8–10 November 2023, Paris, France), Renal Interventions spoke to Gianmarco Falcone (Azienda Ospedaliero Universitaria Careggi, Florence, Italy) about endovascular arteriovenous fistulas (endoAVF) and what he feels is needed to ensure that this relatively “new concept” of vascular access creation is used to its full potential.
VenoStent has announced that the first subjects have been enrolled in the SAVE-FistulaS clinical trial, which will take place at two different sites across the USA; the Surgical Specialists of Charlotte. (Charlotte, USA), and the Cardiothoracic and Vascular Surgeons (Austin, USA).
Ozempic (Novo Nordisk) is a once-daily injection with US Food and Drug Administration (FDA) approval for use as a preventative treatment for strokes and heart attacks in type 2 diabetic patients. Recently, however, the FLOW study has shown that the semaglutide-based drug may also have applications as a preventative treatment for chronic kidney disease (CKD).
Invizius has announced in a press release that the first two patients have been treated with its H-Guard priming solution in the company’s first-in-human Phase 1 clinical study at the National Institute for Health and Care Research (NIHR) Manchester clinical research facility (CRF).
At the 2023 VEITHsymposium (14–18 November, New York, USA), the final day featured a dedicated programme entitled “Improving outcomes in haemodialysis access”, which was made up of five sessions, each covering a different area of haemodialysis access and featuring both presentation and panel discussions led by key opinion leaders in the field.
Fresenius Medical Care recently announced via press release that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its new 5008X haemodialysis system, which they hope will allow them to “bring a new standard of care in dialysis therapy to people living with kidney disease in the USA”.
The first implantation of the VasQ external support device was performed in Greece, Laminate Medical Technologies announced in a press release. The procedure was successfully performed by Alexandros Mallios (Henry Dunant Hospital Center, Athens, Greece).
Koen van der Bogt is a vascular surgeon at Haaglanden Medical Centre (The Hague, The Netherlands) and Leiden University Medical Centre (Leiden, The Netherlands). Joris Rotmans is professor of internal medicine at Leiden University Medical Centre (Leiden, The Netherlands). They write on the promise of dynamic arteriovenous fistulas as a solution to complications caused by high flow-rates.
It’s possible to expand the action radius of a passion for kitesurfing, despite being on long-term dialysis. Pascal Kopperschmidt (Hamburg, Germany) gave attendees at the 5th Hamburg Dialysis Access symposium (8–9 September 2023; Hamburg, Germany) a glimpse of the risks and promises of self-care from a patient’s perspective.
The REDUCED-1 study, a US Food and Drug Administration (FDA) investigational device exemption (IDE)-approved pilot study of the treatment of hypertension with the proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS) system (SoniVie), has completed enrolment.
